Salix Pharmaceuticals Beats Up on Analysts Yet Again
Salix Pharmaceuticals (NAS: SLXP) filed its 10-K on Feb. 28. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Salix Pharmaceuticals beat slightly on revenues and crushed expectations on earnings per share.
Compared to the prior-year quarter, revenue improved significantly and GAAP earnings per share grew significantly.
Margins improved across the board.
Salix Pharmaceuticals notched revenue of $155.2 million. The 17 analysts polled by S&P Capital IQ hoped for revenue of $152.5 million on the same basis. GAAP reported sales were 31% higher than the prior-year quarter's $118.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $1.18. The 16 earnings estimates compiled by S&P Capital IQ averaged $0.94 per share on the same basis. GAAP EPS of $0.55 for Q4 were 49% higher than the prior-year quarter's $0.37 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 82.3%, 530 basis points better than the prior-year quarter. Operating margin was 33.2%, 130 basis points better than the prior-year quarter. Net margin was 21.6%, 90 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $166.2 million. On the bottom line, the average EPS estimate is $0.55.
Next year's average estimate for revenue is $743.1 million. The average EPS estimate is $2.57.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 116 members out of 139 rating the stock outperform, and 23 members rating it underperform. Among 48 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 42 give Salix Pharmaceuticals a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Salix Pharmaceuticals is outperform, with an average price target of $51.88.
The drug and health-care investing landscape is littered with also-rans and a few major winners. Is Salix Pharmaceuticals the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Salix Pharmaceuticals to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.